BridgeBio Awards Grant to Rare Genomics Institute to Help Rare Disease Patients

The Rare Genomics Institute (RG) today announced it has received a grant from BridgeBio Pharma, a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers. RG, a non-profit that makes cutting-edge research technologies and experts accessible to rare disease patients, will use the funds to expand its programs supporting rare disease patients.